Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Data AFFIRM Safety As Well As Survival For MDV3100

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Medivation’s MDV3100 demonstrates a favorable safety profile and hits secondary efficacy endpoints in the AFFIRM study. Drug does not need to be given with prednisone, and could give J&J’s recently launched Zytiga a run for its money.

You may also be interested in...

More Competition In Prostate Cancer? Medivation’s Enzalutamide Now With FDA

Medivation and Astellas have submitted their castration-resistant prostate cancer drug enzalutamide to FDA and hope to gain priority review for the long-anticipated therapy.

J&J’s Zytiga –The Anatomy Of A Cancer Launch

Johnson & Johnson’s prostate cancer drug Zytiga is off to a brilliant launch. Payors are covering it with relatively few restrictions, medical oncologists are using it in advanced patients, and it has streaked ahead of its direct competitor Jevtana, a second-generation taxane, in part by grabbing new patient share from the same post-docetaxel population.

Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time

Phase III data for Medivation's MDV3100 suggest the prostate cancer drug stands to unseat J&J’s market leader Zytiga in many of the disease settings.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts